EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0

作者：

Bennouna, J. ^{[1
]}

Besse, B. ^{[2
]}

Leighl, N. B. ^{[3
]}

Blais, N. ^{[4
]}

Traynor, A. M. ^{[5
]}

Papadimitrakopoulou, V. ^{[6
]}

Klimovsky, J. ^{[7
]}

Jappe, A. ^{[8
]}

Jehl, V. ^{[8
]}

Johnson, B. E. ^{[9
]}

机构：

[1] Ctr Rene Gauducheau, St Herblain, France

[2] Inst Gustave Roussy, Dept Med, Villejuif, France

[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[4] Hop Notre Dame De Bon Secours, CHUM, Montreal, PQ, Canada

[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[6] Univ Texas Houston, Houston, TX USA

[7] Novartis Pharmaceut, Oncol, Florham Pk, NJ USA

[8] Novartis Pharma AG, Oncol, Basel, Switzerland

[9] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：140 / 140

页数：1